|
| 1） |
Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States:lessons from the cancer of the prostate strategic urologic research endeavor（CapSURE）, a national disease registry. J Urol. 2004;171（4）:1393-401. |
| 2） |
Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan:2000 report from the Japanese Urological Association. Int J Urol. 2005;12（1）:46-61. |
| 3） |
Carter CA, Donahue T, Sun L, et al. Temporarily deferred therapy（watchful waiting）for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003;21（21）:4001-8. |
| 4） |
Zietman AL, Thakral H, Wilson L, et al. Conservative management of prostate cancer in the prostate specific antigen era：the incidence and time course of subsequent therapy. J Urol. 2001;166（5）:1702-6. |
| 5） |
Choo R, Klotz L, Danjoux C, et al. Feasibility study:watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002;167（4）:1664-9. |
| 6） |
Bacon CG, Giovannucci E, Testa M, et al. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol. 2001;166（5）:1804-10. |
| 7） |
George N. Therapeutic dilemmas in prostate cancer:justification for watchful waiting. Eur Urol. 1998;34 Suppl 3:33-6. |
| 8） |
Kakehi Y. Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Jpn J Clin Oncol. 2003;33（1）:1-5. |
新検索ページはこちら
ログイン
お問い合わせ
書誌情報
引用文献
